Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$2.23 USD
+0.30 (15.54%)
Updated May 14, 2024 04:00 PM ET
After-Market: $2.22 -0.01 (-0.45%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Pacific Biosciences of California, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 201 | 128 | 131 | 79 | 91 |
Cost Of Goods | 148 | 79 | 72 | 46 | 56 |
Gross Profit | 53 | 49 | 59 | 33 | 35 |
Selling & Adminstrative & Depr. & Amort Expenses | 387 | 356 | 269 | 137 | 135 |
Income After Depreciation & Amortization | -334 | -307 | -210 | -104 | -101 |
Non-Operating Income | 31 | 8 | -52 | 134 | 19 |
Interest Expense | 14 | 15 | 13 | 0 | 3 |
Pretax Income | -318 | -314 | -275 | 29 | -84 |
Income Taxes | -11 | 0 | -94 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -307 | -314 | -181 | 29 | -84 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -307 | -314 | -181 | 29 | -84 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -321 | -289 | -194 | -95 | -90 |
Depreciation & Amortization (Cash Flow) | 14 | 18 | 16 | 9 | 10 |
Income After Depreciation & Amortization | -334 | -307 | -210 | -104 | -101 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 253.63 | 224.55 | 204.14 | 174.97 | 152.53 |
Diluted EPS Before Non-Recurring Items | -1.11 | -1.38 | -0.93 | -0.43 | -0.55 |
Diluted Net EPS (GAAP) | -1.21 | -1.40 | -0.89 | 0.17 | -0.55 |
Fiscal Year end for Pacific Biosciences of California, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 38.81 | 58.36 | 55.69 | 47.57 | 38.90 |
Cost Of Goods | 27.53 | 48.05 | 38.53 | 32.03 | 29.14 |
Gross Profit | 11.28 | 10.31 | 17.16 | 15.55 | 9.76 |
SG&A, R&D, and Dept/Amort Expenses | 92.65 | 97.86 | 99.65 | 88.72 | 101.01 |
Income After SG&A, R&D, and Dept/Amort Expenses | -81.37 | -87.55 | -82.49 | -73.17 | -91.25 |
Non-Operating Income | 6.76 | 8.38 | 8.51 | 6.90 | 6.87 |
Interest Expense | 3.58 | 3.57 | 3.59 | 3.55 | 3.63 |
Pretax Income | -78.18 | -82.74 | -77.58 | -69.83 | -88.02 |
Income Taxes | 0.00 | -0.72 | -10.71 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -78.18 | -82.02 | -66.87 | -69.83 | -88.02 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -78.18 | -82.02 | -66.87 | -69.83 | -88.02 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 269.58 | 267.12 | 255.00 | 250.07 | 242.03 |
Diluted EPS Before Non-Recurring Items | -0.26 | -0.27 | -0.27 | -0.26 | -0.31 |
Diluted Net EPS (GAAP) | -0.29 | -0.31 | -0.26 | -0.28 | -0.36 |